The changes in HNSCC cell lines (e.g., CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main acetylation sites in resistance cell lines. In this study, it was found that the acetylation of STAT1 might hinder the downstream signaling of IFN-γ

Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the acetylation sites in wild-type and resistant cells. We proposed that the acetylation of STAT1 may impair IFN-γ response.